Palisade Bio Q3 Loss Widens to $14.6M; Material Weakness Persists Despite $113.6M Cash
PALI is trading near its 52-week low of $1.08 (3.7% above the low).
Summary
Palisade Bio's Q3 2026 net loss widened to $14.6M on a $10.6M R&D ramp for PALI-2108, but $113.6M of cash is projected to fund operations through the 2027-2028 Phase 2 readouts. The long-standing material weakness in internal controls remains unremediated.
Key Events · Earnings and Guidance · PALI
-
Q3 Loss Widens on Trial Ramp
Net loss was $14.6M for the three months ended September 30, 2026 versus $2.9M a year earlier; nine-month net loss reached $34.8M versus $7.9M.
-
R&D and G&A Step Up Sharply
R&D rose to $10.6M from $1.4M and G&A to $5.1M from $1.5M, driven by PALI-2108 clinical operations, CMC and a $5.1M non-cash stock compensation charge in the quarter.
-
Cash Covers Both Phase 2 Readouts
Cash and equivalents were $113.6M at September 30, 2026, down from $133.4M at year-end 2025; management says this funds operations through the ASCENTRA-UC readout expected Q4 2027 and ASCENTRA-CD expected Q1 2028.
-
Material Weakness Still Unremediated
The material weakness in internal control over financial reporting identified in 2021 remains present as of September 30, 2026, and the CEO concluded disclosure controls were not effective.
Analysis · PALI · Life Sciences
Palisade spent heavily to stand up its PALI-2108 Phase 2 program: quarterly R&D jumped to $10.6M from $1.4M and G&A to $5.1M from $1.5M, pushing the Q3 net loss to $14.6M from $2.9M. The offset is a $113.6M cash pile left over from the October 2025 offering, which management says carries the company through the ASCENTRA-UC efficacy readout expected in Q4 2027 and the ASCENTRA-CD readout expected in Q1 2028 — so there is no near-term financing need, but also no revenue and no cushion beyond those readouts. The governance overhang is that the material weakness in internal controls first identified in 2021 is still unremediated and disclosure controls were again concluded not effective, which keeps reporting risk on the table for a company this small.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 48.1% of the 1752 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PALI was trading at $1.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $196.9M. The 52-week trading range was $1.08 to $2.86. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.